This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Psoriatic Arthritis Treatment Market Size, Trends & Analysis - Forecasts to 2029 By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Immunosuppressants, Biologic Agents, and Others), By Route of Administration (Oral, Parenteral, and Others), and By Region (North America, Asia Pacific, Central and South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global psoriatic arthritis treatment market is projected to grow at a CAGR of 8.3% from 2024 to 2029.
Advancements in the biologics for psoriatic arthritis and targeted medicines are the major factor contributing to the growth of the global market. Biologics, such as TNF inhibitors (etanercept, infliximab) and IL-17 inhibitors (secukinumab), have transformed the psoriatic arthritis therapies landscape by providing more effective and focused approaches to controlling the illness. The introduction of JAK inhibitors has broadened the psoriatic arthritis treatment options for people who may not respond well to standard psoriatic arthritis medications. These drugs have demonstrated great success in lowering inflammation and preventing joint deterioration, which is critical for improving the quality of life for people with psoriatic arthritis. Furthermore, corticosteroids for psoriatic arthritis are effective in controlling acute flare-ups and severe inflammation, adding another vital tool to the therapy arsenal.
In addition to the development of novel pharmaceuticals, the growing emphasis on personalized treatment and combination therapy is fueling market expansion. Personalized medicine in psoriatic arthritis is adapting treatment approaches to each patient's unique traits, including genetic, biomarker, and clinical aspects, which can improve treatment success while reducing side effects. Combination therapy for psoriatic arthritis, which involves employing numerous medications or treatment methods in tandem, can also enhance outcomes by targeting many parts of the disease at the same time. Moreover, topical treatments for psoriatic arthritis, though traditionally focused on skin symptoms, are being integrated into comprehensive treatment regimens to provide additional symptom relief.
Psoriatic arthritis market trends show a growing interest in developing medicines and psoriatic arthritis clinical trials aimed at broadening the spectrum of available remedies. The development of novel biologics and small molecule inhibitors, as well as the investigation of emerging treatments for psoriatic arthritis, are likely to drive innovation in this field. Furthermore, psoriatic arthritis treatment market analysis shows the rising prevalence of psoriatic arthritis pain management solutions and increased awareness of the disorder among healthcare professionals and patients are driving up demand for effective treatments. Additionally, psoriatic arthritis biologics market is a subset of global psoriatic arthritis treatment market and is also expected to boom in the forecast period.
However, the healthcare industry lacks accurate detection techniques for early and conclusive diagnosis of psoriatic arthritis, instead depending on medical observations and elimination processes. Symptoms overlap with diseases such as gout, rheumatoid arthritis, and reactive arthritis, making the psoriatic arthritis market growth trajectory difficult to predict.
The disease-modifying antirheumatic drugs (DMARDs) segment is expected to hold the largest share of the market. The growth of the segment is due to their demonstrated efficacy in slowing disease progression and reducing joint destruction. Conventional and biologic DMARDs are commonly used to treat psoriatic arthritis over time. Their capacity to target underlying inflammation and alter disease progression makes them a cornerstone of treatment, resulting in market dominance.
The immunosuppressants segment is expected to be the fastest-growing segment in the market from 2024 to 2029. The growth is owing to advances in targeted therapy, increased approval of innovative medications, and their efficacy in treating severe instances. These drugs suppress immune system activity, providing new therapeutic choices for patients who have not responded to conventional therapy and driving significant market growth.
The oral segment is anticipated to be the fastest-growing segment in the market from 2024-2029. This growth is due to its convenience, ease of administration, and patient preference for oral drugs over injections or infusions. Advances in oral medication formulations, particularly the introduction of potent small-molecule inhibitors such as JAK inhibitors, improve therapy adherence and efficacy.
The parenteral segment is expected to hold the largest share of the market. The segment's growth is due to the high efficacy and rapid onset of action of injectable treatments, such as biologics and immunosuppressants. These drugs are frequently delivered intravenously or subcutaneously, improving absorption and speedier symptom alleviation. Furthermore, the preference for parenteral administration in severe instances, as well as the advent of new injectable medicines, add to the segment's dominant position.
North America is expected to be the largest region in the market. The primary reasons boosting the market growth in this region include the high prevalence of psoriatic arthritis, a modern healthcare infrastructure that enables early detection and treatment, active research and development efforts, and advantageous reimbursement regulations. Furthermore, as healthcare professionals and patients become more aware of effective treatment choices, the market in North America grows faster than in other regions.
Asia Pacific is predicted to witness rapid growth during the forecast period. Factors driving this trend include rising healthcare expenditure, more knowledge of autoimmune illnesses, and improved healthcare infrastructure in nations such as China, India, and Japan. Furthermore, expanding pharmaceutical industries and a growing emphasis on early detection and effective treatment choices are expected to drive market growth in the Asia Pacific region.
Pfizer Inc., Eisai Inc, UCB Biosciences Inc, Sanofi S.A., Otsuka Pharmaceutical, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Celgene Corporation (Bristol-Myers Squibb), Bayer AG, and AbbVie Inc, among others, are some of the key players operating in the global psoriatic arthritis treatment market.
Please note: This is not an exhaustive list of companies profiled in the report.
In March 2024, Johnson & Johnson submitted a supplemental Biologics License Application (sBLA) to the U.S FDA seeking approval for TREMFYA (guselkumab) to treat adults with moderately to severely active ulcerative colitis (UC). This submission follows positive Phase 3 QUASAR trial results showing that significantly more UC patients achieved clinical remission with TREMFYA compared to placebo.
In December 2023, UCB, a global biopharmaceutical company, achieved a significant milestone with the approval of BIMZELX (bimekizumab) from the Japanese Ministry of Health, Labour and Welfare (MHLW). This approval expands the therapeutic indications of bimekizumab to include the treatment of psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adult patients who have inadequate responses to existing therapies.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Introduction
4.2 Psoriatic Arthritis Therapeutics Market: Drug Class Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
4.4.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Disease-Modifying Antirheumatic Drugs (DMARDs)
4.5.1 Disease-Modifying Antirheumatic Drugs (DMARDs) Market Estimates and Forecast, 2021-2029 (USD Million)
4.6 Immunosuppressants
4.6.1 Immunosuppressants Market Estimates and Forecast, 2021-2029 (USD Million)
4.7 Biologic Agents
4.7.1 Biologic Agents Market Estimates and Forecast, 2021-2029 (USD Million)
4.8 Others
5 GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Introduction
5.2 Psoriatic Arthritis Therapeutics Market: Route of Administration Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Oral
5.4.1 Oral Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Parenteral
5.5.1 Parenteral Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Others
5.6.1 Others Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET, BY REGION
6.1 Introduction
6.2 North America Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.1 By Drug Class
6.2.2 By Route of Administration
6.2.3 By Country
6.2.3.1 U.S. Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.1.1 By Drug Class
6.2.3.1.2 By Route of Administration
6.2.3.2 Canada Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.2.1 By Drug Class
6.2.3.2.2 By Route of Administration
6.2.3.3 Mexico Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.2.3.3.1 By Drug Class
6.2.3.3.2 By Route of Administration
6.3 Europe Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.1 By Drug Class
6.3.2 By Route of Administration
6.3.3 By Country
6.3.3.1 Germany Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.1.1 By Drug Class
6.3.3.1.2 By Route of Administration
6.3.3.2 U.K. Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.2.1 By Drug Class
6.3.3.2.2 By Route of Administration
6.3.3.3 France Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.3.1 By Drug Class
6.3.3.3.2 By Route of Administration
6.3.3.4 Italy Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.4.1 By Drug Class
6.3.3.4.2 By Route of Administration
6.3.3.5 Spain Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.5.1 By Drug Class
6.3.3.5.2 By Route of Administration
6.3.3.6 Netherlands Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Drug Class
6.3.3.6.2 By Route of Administration
6.3.3.7 Rest of Europe Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.3.3.6.1 By Drug Class
6.3.3.6.2 By Route of Administration
6.4 Asia Pacific Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.1 By Drug Class
6.4.2 By Route of Administration
6.4.3 By Country
6.4.3.1 China Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.1.1 By Drug Class
6.4.3.1.2 By Route of Administration
6.4.3.2 Japan Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.2.1 By Drug Class
6.4.3.2.2 By Route of Administration
6.4.3.3 India Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.3.1 By Drug Class
6.4.3.3.2 By Route of Administration
6.4.3.4 South Korea Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.4.1 By Drug Class
6.4.3.4.2 By Route of Administration
6.4.3.5 Singapore Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.5.1 By Drug Class
6.4.3.5.2 By Route of Administration
6.4.3.6 Malaysia Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Drug Class
6.4.3.6.2 By Route of Administration
6.4.3.7 Thailand Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.6.1 By Drug Class
6.4.3.6.2 By Route of Administration
6.4.3.8 Indonesia Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.7.1 By Drug Class
6.4.3.7.2 By Route of Administration
6.4.3.9 Vietnam Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.8.1 By Drug Class
6.4.3.8.2 By Route of Administration
6.4.3.10 Taiwan Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.10.1 By Drug Class
6.4.3.10.2 By Route of Administration
6.4.3.11 Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.4.3.11.1 By Drug Class
6.4.3.11.2 By Route of Administration
6.5 Middle East and Africa Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.1 By Drug Class
6.5.2 By Route of Administration
6.5.3 By Country
6.5.3.1 Saudi Arabia Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.1.1 By Drug Class
6.5.3.1.2 By Route of Administration
6.5.3.2 U.A.E. Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.2.1 By Drug Class
6.5.3.2.2 By Route of Administration
6.5.3.3 Israel Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.3.1 By Drug Class
6.5.3.3.2 By Route of Administration
6.5.3.4 South Africa Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.4.1 By Drug Class
6.5.3.4.2 By Route of Administration
6.5.3.5 Rest of Middle East and Africa Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.5.3.5.1 By Drug Class
6.5.3.5.2 By Route of Administration
6.6 Central and South America Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.1 By Drug Class
6.6.2 By Route of Administration
6.6.3 By Country
6.6.3.1 Brazil Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.1.1 By Drug Class
6.6.3.1.2 By Route of Administration
6.6.3.2 Argentina Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.2.1 By Drug Class
6.6.3.2.2 By Route of Administration
6.6.3.3 Chile Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Drug Class
6.6.3.3.2 By Route of Administration
6.6.3.3 Rest of Central and South America Psoriatic Arthritis Therapeutics Market Estimates and Forecast, 2021-2029 (USD Million)
6.6.3.3.1 By Drug Class
6.6.3.3.2 By Route of Administration
7 COMPETITIVE LANDCAPE
7.1 Company Market Share Analysis
7.2 Four Quadrant Positioning Matrix
7.2.1 Market Leaders
7.2.2 Market Visionaries
7.2.3 Market Challengers
7.2.4 Niche Market Players
7.3 Vendor Landscape
7.3.1 North America
7.3.2 Europe
7.3.3 Asia Pacific
7.3.4 Rest of the World
7.4 Company Profiles
7.4.1 Pfizer Inc.
7.4.1.1 Business Description & Financial Analysis
7.4.1.2 SWOT Analysis
7.4.1.3 Products & Services Offered
7.4.1.4 Strategic Alliances between Business Partners
7.4.2 Eisai Inc
7.4.2.1 Business Description & Financial Analysis
7.4.2.2 SWOT Analysis
7.4.2.3 Products & Services Offered
7.4.2.4 Strategic Alliances between Business Partners
7.4.3 UCB Biosciences Inc
7.4.3.1 Business Description & Financial Analysis
7.4.3.2 SWOT Analysis
7.4.3.3 Products & Services Offered
7.4.3.4 Strategic Alliances between Business Partners
7.4.4 Sanofi S.A.
7.4.4.1 Business Description & Financial Analysis
7.4.4.2 SWOT Analysis
7.4.4.3 Products & Services Offered
7.4.4.4 Strategic Alliances between Business Partners
7.4.5 Otsuka Pharmaceutical
7.4.5.1 Business Description & Financial Analysis
7.4.5.2 SWOT Analysis
7.4.5.3 Products & Services Offered
7.4.5.4 Strategic Alliances between Business Partners
7.4.6 Sumitomo Dainippon Pharma Co
7.4.6.1 Business Description & Financial Analysis
7.4.6.2 SWOT Analysis
7.4.6.3 Products & Services Offered
7.4.6.4 Strategic Alliances between Business Partners
7.4.7 Johnson & Johnson
7.4.7.1 Business Description & Financial Analysis
7.4.7.2 SWOT Analysis
7.4.7.3 Products & Services Offered
7.4.7.4 Strategic Alliances between Business Partners
7.4.8 Celgene Corporation (Bristol-Myers Squibb)
7.4.8.1 Business Description & Financial Analysis
7.4.8.2 SWOT Analysis
7.4.8.3 Products & Services Offered
7.4.8.4 Strategic Alliances between Business Partners
7.4.9 AbbVie Inc
7.4.9.1 Business Description & Financial Analysis
7.4.9.2 SWOT Analysis
7.4.9.3 Products & Services Offered
7.4.9.4 Strategic Alliances between Business Partners
7.4.10 Bayer AG
7.4.10.1 Business Description & Financial Analysis
7.4.10.2 SWOT Analysis
7.4.10.3 Products & Services Offered
7.4.10.4 Strategic Alliances between Business Partners
7.4.11 Other Companies
7.4.11.1 Business Description & Financial Analysis
7.4.11.2 SWOT Analysis
7.4.11.3 Products & Services Offered
7.4.11.4 Strategic Alliances between Business Partners
8 RESEARCH METHODOLOGY
8.1 Market Introduction
8.1.1 Market Definition
8.1.2 Market Scope & Segmentation
8.2 Information Procurement
8.2.1 Secondary Research
8.2.1.1 Purchased Databases
8.2.1.2 GMEs Internal Data Repository
8.2.1.3 Secondary Resources & Third Party Perspectives
8.2.1.4 Company Information Sources
8.2.2 Primary Research
8.2.2.1 Various Types of Respondents for Primary Interviews
8.2.2.2 Number of Interviews Conducted throughout the Research Process
8.2.2.3 Primary Stakeholders
8.2.2.4 Discussion Guide for Primary Participants
8.2.3 Expert Panels
8.2.3.1 Expert Panels Across 30+ Industry
8.2.4 Paid Local Experts
8.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
8.3 Market Estimation
8.3.1 Top-Down Approach
8.3.1.1 Macro-Economic Indicators Considered
8.3.1.2 Micro-Economic Indicators Considered
8.3.2 Bottom Up Approach
8.3.2.1 Company Share Analysis Approach
8.3.2.2 Estimation of Potential Product Sales
8.4 Data Triangulation
8.4.1 Data Collection
8.4.2 Time Series, Cross Sectional & Panel Data Analysis
8.4.3 Cluster Analysis
8.5 Analysis and Output
8.5.1 Inhouse AI Based Real Time Analytics Tool
8.5.2 Output From Desk & Primary Research
8.6 Research Assumptions & Limitations
8.6.1 Research Assumptions
8.6.2 Research Limitations
LIST OF TABLES
1 Global Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Region, 2021-2029 (USD Million)
3 Disease-Modifying Antirheumatic Drugs (DMARDs) Market, By Region, 2021-2029 (USD Million)
4 Biologic Agents Market, By Region, 2021-2029 (USD Million)
5 Immunosuppressants Market, By Region, 2021-2029 (USD Million)
6 Others Market, By Region, 2021-2029 (USD Million)
7 Global Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
8 Oral Market, By Region, 2021-2029 (USD Million)
9 Parenteral Market, By Region, 2021-2029 (USD Million)
10 Others Market, By Region, 2021-2029 (USD Million)
11 Regional Analysis, 2021-2029 (USD Million)
12 North America Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
13 North America Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
14 North America Psoriatic Arthritis Therapeutics Market, By COUNTRY, 2021-2029 (USD Million)
15 U.S. Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
16 U.S. Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
17 Canada Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
18 Canada Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
19 Mexico Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
20 Mexico Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
21 Europe Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
22 Europe Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
23 Europe Psoriatic Arthritis Therapeutics Market, By Country, 2021-2029 (USD Million)
24 Germany Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
25 Germany Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
26 U.K. Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
27 U.K. Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
28 France Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
29 France Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
30 Italy Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
31 Italy Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
32 Spain Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
33 Spain Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
34 Netherlands Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
35 Netherlands Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
36 Rest Of Europe Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
37 Rest Of Europe Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
38 Asia Pacific Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
39 Asia Pacific Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
40 Asia Pacific Psoriatic Arthritis Therapeutics Market, By Country, 2021-2029 (USD Million)
41 China Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
42 China Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
43 Japan Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
44 Japan Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
45 India Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
46 India Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
47 South Korea Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
48 South Korea Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
49 Singapore Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
50 Singapore Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
51 Thailand Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
52 Thailand Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
53 Malaysia Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
54 Malaysia Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
55 Indonesia Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
56 Indonesia Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
57 Vietnam Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
58 Vietnam Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
59 Taiwan Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
60 Taiwan Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
61 Rest of APAC Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
62 Rest of APAC Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
63 Middle East and Africa Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
64 Middle East and Africa Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
65 Middle East and Africa Psoriatic Arthritis Therapeutics Market, By Country, 2021-2029 (USD Million)
66 Saudi Arabia Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
67 Saudi Arabia Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
68 UAE Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
69 UAE Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
70 Israel Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
71 Israel Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
72 South Africa Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
73 South Africa Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
74 Rest Of Middle East and Africa Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
75 Rest Of Middle East and Africa Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
76 Central and South America Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
77 Central and South America Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
78 Central and South America Psoriatic Arthritis Therapeutics Market, By Country, 2021-2029 (USD Million)
79 Brazil Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
80 Brazil Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
81 Chile Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
82 Chile Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
83 Argentina Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
84 Argentina Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
85 Rest Of Central and South America Psoriatic Arthritis Therapeutics Market, By Drug Class, 2021-2029 (USD Million)
86 Rest Of Central and South America Psoriatic Arthritis Therapeutics Market, By Route of Administration, 2021-2029 (USD Million)
87 Pfizer Inc.: Products & Services Offering
88 Eisai Inc: Products & Services Offering
89 UCB Biosciences Inc: Products & Services Offering
90 Sanofi S.A.: Products & Services Offering
91 Otsuka Pharmaceutical: Products & Services Offering
92 SUMITOMO DAINIPPON PHARMA CO: Products & Services Offering
93 Johnson & Johnson : Products & Services Offering
94 Celgene Corporation (Bristol-Myers Squibb): Products & Services Offering
95 AbbVie Inc, Inc: Products & Services Offering
96 Bayer AG: Products & Services Offering
97 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Psoriatic Arthritis Therapeutics Market Overview
2 Global Psoriatic Arthritis Therapeutics Market Value From 2021-2029 (USD Million)
3 Global Psoriatic Arthritis Therapeutics Market Share, By Drug Class (2023)
4 Global Psoriatic Arthritis Therapeutics Market Share, By Route of Administration (2023)
5 Global Psoriatic Arthritis Therapeutics Market, By Region (Asia Pacific Market)
6 Technological Trends In Global Psoriatic Arthritis Therapeutics Market
7 Four Quadrant Competitor Positioning Matrix
8 Impact Of Macro & Micro Indicators On The Market
9 Impact Of Key Drivers On The Global Psoriatic Arthritis Therapeutics Market
10 Impact Of Challenges On The Global Psoriatic Arthritis Therapeutics Market
11 Porter’s Five Forces Analysis
12 Global Psoriatic Arthritis Therapeutics Market: By Drug Class Scope Key Takeaways
13 Global Psoriatic Arthritis Therapeutics Market, By Drug Class Segment: Revenue Growth Analysis
14 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market, By Region, 2021-2029 (USD Million)
15 Disease-Modifying Antirheumatic Drugs (DMARDs) Market, By Region, 2021-2029 (USD Million)
16 Biologic AgentsMarket, By Region, 2021-2029 (USD Million)
17 Immunosuppressants Market, By Region, 2021-2029 (USD Million)
18 Others Market, By Region, 2021-2029 (USD Million)
19 Global Psoriatic Arthritis Therapeutics Market: By Route of Administration Scope Key Takeaways
20 Global Psoriatic Arthritis Therapeutics Market, By Route of Administration Segment: Revenue Growth Analysis
21 Oral Market, By Region, 2021-2029 (USD Million)
22 Parenteral Market, By Region, 2021-2029 (USD Million)
23 Others Market, By Region, 2021-2029 (USD Million)
24 Regional Segment: Revenue Growth Analysis
25 Global Psoriatic Arthritis Therapeutics Market: Regional Analysis
26 North America Psoriatic Arthritis Therapeutics Market Overview
27 North America Psoriatic Arthritis Therapeutics Market, By Drug Class
28 North America Psoriatic Arthritis Therapeutics Market, By Route of Administration
29 North America Psoriatic Arthritis Therapeutics Market, By Country
30 U.S. Psoriatic Arthritis Therapeutics Market, By Drug Class
31 U.S. Psoriatic Arthritis Therapeutics Market, By Route of Administration
32 Canada Psoriatic Arthritis Therapeutics Market, By Drug Class
33 Canada Psoriatic Arthritis Therapeutics Market, By Route of Administration
34 Mexico Psoriatic Arthritis Therapeutics Market, By Drug Class
35 Mexico Psoriatic Arthritis Therapeutics Market, By Route of Administration
36 Four Quadrant Positioning Matrix
37 Company Market Share Analysis
38 Pfizer Inc.: Company Snapshot
39 Pfizer Inc.: SWOT Analysis
40 Pfizer Inc.: Geographic Presence
41 Eisai Inc: Company Snapshot
42 Eisai Inc: SWOT Analysis
43 Eisai Inc: Geographic Presence
44 UCB Biosciences Inc: Company Snapshot
45 UCB Biosciences Inc: SWOT Analysis
46 UCB Biosciences Inc: Geographic Presence
47 Sanofi S.A.: Company Snapshot
48 Sanofi S.A.: Swot Analysis
49 Sanofi S.A.: Geographic Presence
50 Otsuka Pharmaceutical: Company Snapshot
51 Otsuka Pharmaceutical: SWOT Analysis
52 Otsuka Pharmaceutical: Geographic Presence
53 Sumitomo Dainippon Pharma Co: Company Snapshot
54 Sumitomo Dainippon Pharma Co: SWOT Analysis
55 Sumitomo Dainippon Pharma Co: Geographic Presence
56 Johnson & Johnson : Company Snapshot
57 Johnson & Johnson : SWOT Analysis
58 Johnson & Johnson : Geographic Presence
59 Celgene Corporation (Bristol-Myers Squibb): Company Snapshot
60 Celgene Corporation (Bristol-Myers Squibb): SWOT Analysis
61 Celgene Corporation (Bristol-Myers Squibb): Geographic Presence
62 AbbVie Inc, Inc.: Company Snapshot
63 AbbVie Inc, Inc.: SWOT Analysis
64 AbbVie Inc, Inc.: Geographic Presence
65 Bayer AG: Company Snapshot
66 Bayer AG: SWOT Analysis
67 Bayer AG: Geographic Presence
68 Other Companies: Company Snapshot
69 Other Companies: SWOT Analysis
70 Other Companies: Geographic Presence
The Global Psoriatic Arthritis Treatment Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Psoriatic Arthritis Treatment Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
